These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. Anikwue R; Huffman JW; Martin ZL; Welch SP J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269 [TBL] [Abstract][Full Text] [Related]
5. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444 [TBL] [Abstract][Full Text] [Related]
6. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
7. Assessment of dependence potential and abuse liability of Δ Vanegas SO; Reck AM; Rodriguez CE; Marusich JA; Yassin O; Sotzing G; Wiley JL; Kinsey SG Drug Alcohol Depend; 2022 Nov; 240():109640. PubMed ID: 36179506 [TBL] [Abstract][Full Text] [Related]
8. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Marshell R; Kearney-Ramos T; Brents LK; Hyatt WS; Tai S; Prather PL; Fantegrossi WE Pharmacol Biochem Behav; 2014 Sep; 124():40-7. PubMed ID: 24857780 [TBL] [Abstract][Full Text] [Related]
9. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration. Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755 [TBL] [Abstract][Full Text] [Related]
10. MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice. Crowe MS; Kinsey SG Eur J Pharmacol; 2017 Jul; 807():198-204. PubMed ID: 28478068 [TBL] [Abstract][Full Text] [Related]
11. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. McMahon LR; Koek W Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol. DeLong GT; Wolf CE; Poklis A; Lichtman AH Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971 [TBL] [Abstract][Full Text] [Related]
13. Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. Wakley AA; Wiley JL; Craft RM Drug Alcohol Depend; 2014 Oct; 143():22-8. PubMed ID: 25131716 [TBL] [Abstract][Full Text] [Related]
14. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids. Janoyan JJ; Crim JL; Darmani NA Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518 [TBL] [Abstract][Full Text] [Related]
15. β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Nguyen PT; Schmid CL; Raehal KM; Selley DE; Bohn LM; Sim-Selley LJ Biol Psychiatry; 2012 Apr; 71(8):714-24. PubMed ID: 22264443 [TBL] [Abstract][Full Text] [Related]
16. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. Smith PB; Welch SP; Martin BR J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952 [TBL] [Abstract][Full Text] [Related]
17. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. Welch SP; Dunlow LD; Patrick GS; Razdan RK J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096 [TBL] [Abstract][Full Text] [Related]
18. Cannabimimetic properties of ajulemic acid. Vann RE; Cook CD; Martin BR; Wiley JL J Pharmacol Exp Ther; 2007 Feb; 320(2):678-86. PubMed ID: 17105826 [TBL] [Abstract][Full Text] [Related]